


NICE nods through Daiichi Sankyo's cholesterol drugs



18-03-2021

The National Institute for Health and Care Excellence (NICE) has issued a Final Appraisal Document (FAD) recommending the provision of Nilemdo (bempedoic acid) and Nustendi (bempedoic acid/ ezetimibe) on the National Health Service (NHS) in England.

Daiichi Sankyo's (TYO: 4568) two drugs have been recommended for treating primary hypercholesterolemia or mixed dyslipidemia (heterozygous familial and non-familial) as an adjunct to diet, only if statins are contraindicated or not tolerated, and ezetimibe alone does not control low-density lipoprotein cholesterol (LDL-C) well enough.

"Availability of treatments such as these is essential in tackling cardiovascular disease"

This recommendation is an important milestone for patients who will have access to two important new treatment options for lowering LDL-C, a leading risk factor for cardiovascular events, such as heart attack or stroke.

Cardiovascular disease is one of the main causes of death and disability in the UK, with more than seven million people affected, and it is estimated that close to half of the adult population are living with cholesterol levels above national guidelines.

England is the first country in Europe to be granted access.

Kausik Ray, professor of public health and honorary consultant cardiologist, Imperial College London, said: "Until now, patients with hypercholesterolemia who cannot tolerate statins have had limited treatment options to effectively reduce their LDL-C levels, which is a

modifiable risk factor of cardiovascular disease.

“Today’s announcement is fantastic news for patients as it marks the first new oral treatment options for high cholesterol to be made available over a decade. Availability of treatments such as these is essential in tackling cardiovascular disease, the leading cause of death in the UK. When it comes to heart health and cholesterol, there is no such thing as ‘too low LDL-C’, highlighting the importance of treatments for high-risk patients.”

◀ Cardio-vascular ▶ Daiichi Sankyo ▶ Focus On ▶ Japan ▶ Nilembo ▶ Nustendi ▶ Pharmaceutical ▶ Pricing, reimbursement and access ▶ UK
